Finview.ru
iv-g (Нефтегаз)
spydell
Михаил Хазин (khazin)
Редакция
so-l.ru Аналитика
Рупор тоталитарной пропаганды (colonelcassad)
Капитан ТС (vbulahtin)
Правосудия.нет
ИЗБОРСКИЙ КЛУБ
T. Rowe Price Japan Fund (PRJPX) in Focus
- 0
T. Rowe Price Japan (PRJPX) a Zacks Rank #1 (Strong Buy) seeks long-term growth of capital through investment in common stocks of large and small companies domiciled or with primary operations in Japan
Quick Guide to BlackRock Allocation Target Shares Series C Fund (BRACX)
- 0
BlackRock Allocation Target Shares Series C (BRACX) a Zacks Rank #1 (Strong Buy) invests in the following securities: corporate bonds, notes and debentures; asset-backed securities; commercial and residential mortgage-backed securities
Overview of MassMutual Select Mid Cap Growth Administrative Fund (MMELX)
- 0
MassMutual Select Mid Cap Growth Administrative (MMELX) a Zacks Rank #1 (Strong Buy) seeks growth of capital over the long-term.
Guide to PIMCO RAE Fundamental PLUS C Fund (PIXCX)
- 0
PIMCO RAE Fundamental PLUS C (PIXCX) a Zacks Rank #1 (Strong Buy) seeks to exceed the total return of the S&P 500 Index under normal circumstances by obtaining exposure to a portfolio of stocks of U.S. companies
How is TIAA-CREF Mid-Cap Value Premier Fund (TRVPX) Performing?
- 0
TIAA-CREF Mid-Cap Value Premier (TRVPX) a Zacks Rank #1 (Strong Buy) invests at least 80% of its assets in mid-cap equity securities
Why Is People's United (PBCT) Down 4.6% Since the Last Earnings Report?
- 0
People's United (PBCT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Market Inches Higher Again On Little News Flow
- 0
. Investors have turned their attention to earnings as economic data is a little dry this week
The Best Buying Opportunities in the Apparel Retail Stocks
- 0
Tracey Ryniec and Maddy Johnson discuss the good, the bad, and the ugly among the apparel retail stocks.
5 Must See Earnings Charts
- 0
It's not easy to beat nearly every quarter for 5 years but these companies are doing it.
BioLineRx Makes Regulatory Submission for Trial of BL-8040
- 0
BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).